Skip to main content
Equibles
CBIH logo

CBIH · Cannabis Bioscience International Holdings, Inc.

Track CBIH — free

Use CBIH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CBIH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+0.00%) At close · Oct 16
Rebalance outlook locked
Going-concern doubt — flagged Apr 16, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As indicated in Note 3 of the notes to the audited consolidated financial statements for the period ended February 28, 2026, and the report thereon of the Company's independent auditing firm, there is substantial doubt as to the ability of the Company to continue as a going concern.”
View the 10-Q filed Apr 16, 2026
Market Cap
$1.74M
Shares
11.63B
Volume · Oct 16 20K Avg daily vol (3M) 4.09M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.00 Open$0.00 Day$0.00–0.00 52W close$0.00–0.00 Avg vol 30d946K Short int10K · 0.0% float · 1.0d Short vol78% DataJan 2020–Oct 2026 Filing10-Q · Apr 16

Up next

Latest filing: 10-Q
filed Apr 16, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$123,627
Trailing 12 months
Net income (TTM)
−$515,288
Trailing 12 months
Revenue growth YoY
-25.0%
Year over year
Operating margin
-322.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$264,002
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.4%
Year over year · more shares
Price change (1Y)
-60.0%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 115 metrics

Quarterly results

Revenue Net income Net loss
· $75,861 −$135,935 '24 Q4* ▲145.7% $178,887 −$76,305 '25 Q1 ▲16.5% $74,248 −$79,528 '25 Q2 ▼59% $14,931 −$181,243 '25 Q3 ▼53.9% $34,956 −$211,744 '25 Q4* ▼86.5% $24,200 −$82,645 '26 Q1 ▼28.3% $53,266 −$116,966 '26 Q2 LATEST ▼25% $11,205 −$103,933 '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 20 · elevated Equity put/call 0.65
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −50%
below
Price vs 50-day avg 0%
above
RSI (14) 53
neutral
MACD trend Negative
52-week position 17%
mid-range
Momentum
relative strength
Very Weak
1-month return 0%
trailing
6-month return −50%
trailing
YTD return −60%
this year
Relative strength −57%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 31
low risk · 0–100
Fundamentals
Strong
Revenue growth +22%
Y/Y
Gross margin 87%
expanding
EPS growth +17%
Y/Y
Balance sheet $251.1K
net debt
Quant / Vol
risk profile
High
Volatility 379%
annualized · 1-yr
Max drawdown −86%
past year
ATR 0.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−50% Bearish
Price vs 50-day avg
0% Neutral
RSI (14)
53 Neutral
MACD trend
Negative Bearish
52-week position
17% Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 17% Range high $0
vs 200-day avg -50% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CBIH
Cannabis Bioscience International Holdings, Inc.
this stock
$1.74M -60.0% +21.8% — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $62.84B +25.8% — — 0.1%
GALDY
Galderma Group AG/ADR
 $49.52B +2.5% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $48.36B +32.4% +4.3% 68.0 2.6%
HLN
Haleon plc
 $44.55B +0.3% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
10.0K
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
78%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
4.4M
Value
$0
As of
Apr 30, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$303.0K
Net income (FY)
$-548.8K
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
10-Q
Filed
Apr 16, 2026
This year
2
View
Proposed Sales
Value
$12.5K
Shares
50.0M
Filed
May 11, 2026
View

Performance

5D 20D 120D MTD YTD
CBIH +0.0% +0.0% -50.0% +0.0% -60.0%
SPY -2.0% +0.2% +6.7% +0.1% +11.9%
vs SPY +2.0% -0.2% -56.7% -0.1% -71.9%
Key facts CIK 1411057 CUSIP 16948K106 Visit website Investor relations